Study of the potential reversal of triazolam memory and cognitive deficits by RU 41 656 in healthy subjects.
The potential antagonism of a single oral dose of RU 41 656 (10 mg) on the memory and attention disturbances induced by oral administration of triazolam (0.25 mg) have been investigated in a 3-period, placebo controlled, double blind, cross-over study involving 12 healthy young volunteers. The effects of the compounds were evaluated by objective tests (Buschke selective reminding test, CFF, simple reaction time, tapping, arithmetical calculation) and subjective measurements (visual analogue scale, side effects questionnaire). Measurements were taken before treatment and 2, 4 and 7 h after RU 41 656 intake. Triazolam caused anterograde amnesia as already described with other benzodiazepine with few sedative effects at this dosage. Under the experimental conditions of the trial, RU 41 656 failed to counteract the memory deficits induced by triazolam.
Patat
A
A
Clinical Pharmacology, Roussel UCLAF Medical Department, Romainville, France.
Klein
M J
MJ
Surjus
A
A
Hucher
M
M
Granier
J
J
D000328:Adult; D001288:Attention / Q000187:drug effects; D003072:Cognition Disorders / Q000139:chemically induced / Q000188:drug therapy*; D004311:Double-Blind Method; D004644:Emotions / Q000187:drug effects; D004873:Ergolines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D005425:Flicker Fusion / Q000187:drug effects; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects; D008569:Memory Disorders / Q000139:chemically induced / Q000188:drug therapy*; D011597:Psychomotor Performance / Q000187:drug effects; D011930:Reaction Time / Q000187:drug effects; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology*; D017448:Receptors, Dopamine D2; D012016:Reference Values; D014229:Triazolam / Q000037:antagonists & inhibitors* / Q000494:pharmacology
D004873:Ergolines; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; C070562:RU 41656; D014229:Triazolam